Triterpenoid Dihydro-CDDO-Trifluoroethyl Amide Protects against Maladaptive Cardiac Remodeling and Dysfunction in Mice: A Critical Role of Nrf2

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Xing, Yifan ^a,b   Niu, Ting ^a   Wang, Wenjuan ^a,b   Li, Jinqing ^b   Li, Siying ^a,b   Janicki, Joseph S ^b   Ruiz, Stacey ^c   Meyer, Colin J ^c   Wang, Xing Li ^a   Tang, Dongqi ^a,b   Zhao, Yuxia ^a   Cui, Taixing ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Reata Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN II; CARDIAC AGENT; DH 404; DIHYDRO BARDOXOLONE TRIFLUOROETHYLAMIDE; HYDROGEN PEROXIDE; MESSENGER RNA; NORADRENALIN; PHENYLEPHRINE; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FETUS; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE SILENCING; HEART CELL CULTURE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEWBORN; NONHUMAN; NRF2 GENE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL NUCLEUS; CONSTRICTION; FIBROSIS; HEART; HEART FAILURE; HYPERTROPHY; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; OXIDATIVE STRESS; PRESSURE; UP-REGULATION; VENTRICULAR REMODELING;

MUS; RATTUS;

EID: 84866456998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044899     Document Type: Article

References (31)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, et al. (2008) Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25-146.
2. Swynghedauw B, (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262.
3. Cohn JN, Ferrari R, Sharpe N, (2000) Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35: 569-582.
4. Mudd JO, Kass DA, (2008) Tackling heart failure in the twenty-first century. Nature 451: 919-928.
5. Landmesser U, Wollert KC, Drexler H, (2009) Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 81: 519-527.
6. Takimoto E, Kass DA, (2007) Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49: 241-248.
7. Murdoch CE, Zhang M, Cave AC, Shah AM, (2006) NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 71: 208-215.
8. Giordano FJ, (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115: 500-508.
9. Jialal I, Devaraj S, (2003) Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 107: 926-928.
10. Madamanchi NR, Vendrov A, Runge MS, (2005) Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25: 29-38.
11. Gutierrez J, Ballinger SW, Darley-Usmar VM, Landar A, (2006) Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res 99: 924-932.
12. Guzik TJ, Harrison DG, (2006) Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 11: 524-533.
13. Li J, Ichikawa T, Janicki JS, Cui T, (2009) Targeting the Nrf2 pathway against cardiovascular disease. Expert Opin Ther Targets 13: 785-794.
14. Wiesel P, Patel AP, Carvajal IM, Wang ZY, Pellacani A, et al. (2001) Exacerbation of chronic renovascular hypertension and acute renal failure in heme oxygenase-1-deficient mice. Circ Res 88: 1088-1094.
15. Hu CM, Chen YH, Chiang MT, Chau LY, (2004) Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo. Circulation 110: 309-316.
16. Lu Z, Xu X, Hu X, Zhu G, Zhang P, et al. (2008) Extracellular superoxide dismutase deficiency exacerbates pressure overload-induced left ventricular hypertrophy and dysfunction. Hypertension 51: 19-25.
17. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, et al. (2006) Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 291: H2237-2245.
18. Li J, Ichikawa T, Villacorta L, Janicki JS, Brower GL, et al. (2009) Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 29: 1843-1850.
19. Li J, Zhang C, Xing Y, Janicki JS, Yamamoto M, et al. (2011) Up-regulation of p27(kip1) contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy. Cardiovasc Res 90: 315-324.
20. Tan Y, Ichikawa T, Li J, Si Q, Yang H, et al. (2011) Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60: 625-633.
21. Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, et al. (2010) Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation 122: 11-19.
22. Zhang Y, Sano M, Shinmura K, Tamaki K, Katsumata Y, et al. (2010) 4-hydroxy-2-nonenal protects against cardiac ischemia-reperfusion injury via the Nrf2-dependent pathway. J Mol Cell Cardiol 49: 576-586.
23. Li J, Ichikawa T, Jin Y, Hofseth LJ, Nagarkatti P, et al. (2010) An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes. J Ethnopharmacol 130: 222-230.
24. Ichikawa T, Li J, Meyer CJ, Janicki JS, Hannink M, et al. (2009) Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes. PLoS One 4: e8391.
25. Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, et al. (2009) Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci U S A 106: 250-255.
26. Piao CS, Gao S, Lee GH, Kim do S, Park BH, et al. (2010) Sulforaphane protects ischemic injury of hearts through antioxidant pathway and mitochondrial K(ATP) channels. Pharmacol Res 61: 342-348.
27. Liby KT, Yore MM, Sporn MB, (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369.
28. Saha PK, Reddy VT, Konopleva M, Andreeff M, Chan L, (2010) The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem 285: 40581-40592.
29. Zhang P, Hu X, Xu X, Fassett J, Zhu G, et al. (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52: 918-924.
30. Xie Z, He C, Zou MH, (2011) AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy. Autophagy 7: 1254-1255.
31. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336.